for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Linical Co., Ltd.

2183.T

Latest Trade

1,007.00JPY

Change

4.00(+0.40%)

Volume

100,800

Today's Range

985.00

 - 

1,025.00

52 Week Range

861.00

 - 

1,789.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,003.00
Open
1,002.00
Volume
100,800
3M AVG Volume
1.36
Today's High
1,025.00
Today's Low
985.00
52 Week High
1,789.00
52 Week Low
861.00
Shares Out (MIL)
22.59
Market Cap (MIL)
25,630.64
Forward P/E
25.42
Dividend (Yield %)
1.16

Next Event

Q3 2020 Linical Co Ltd Earnings Release

Latest Developments

More

Linical: To Buy Back Up To 100 Million Yen Of Its Own Shares Through Jan 31

Linical unit to buy Accelovance for 3.47 bln yen

Linical unit sets up unit LINICAL Czech Republic s.r.o.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Linical Co., Ltd.

Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Industry

Biotechnology & Drugs

Contact Info

10F, Shin-Osaka Brick Bldg

1-6-1, Miyahara

Yodogawa-ku

+81.6.61502478

https://www.linical.co.jp/

Executive Leadership

Kazuhiro Hatano

President, Chief Director of Development, Representative Director

Akihiro Takahashi

Senior Managing Director, Chief Financial Officer, Chief Director of Administration

Keigo Tsujimoto

Vice President, Manager of International Business Development Office, President of Subsidiary, Director

Jun Kawai

Senior Managing Director, Deputy Chief Director of Development (Osaka), Director of 3rd Development, Chairman & President of Subsidiaries

Yoshio Kaji

Managing Director, Manager of Business Planning Office

Key Stats

1.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

63.590

2018

57.020

2019

25.089

2020(E)

40.750
Price To Earnings (TTM)
43.34
Price To Sales (TTM)
2.28
Price To Book (MRQ)
4.76
Price To Cash Flow (TTM)
26.06
Total Debt To Equity (MRQ)
107.32
LT Debt To Equity (MRQ)
68.26
Return on Investment (TTM)
7.20
Return on Equity (TTM)
3.95

Latest News

Latest News

BRIEF-Linical to take out loans of 4 bln yen

* Says it will take out loans of 4 billion yen in total, on April 12, due to unit LINICAL USA, INC will acquire stake in Accelovance, Inc

BRIEF-Linical unit to buy Accelovance for 3.47 bln yen

* Says its wholly owned subsidiary LINICAL USA INC and LINICAL USA's wholly owned subsidiary Magnolia Acquisition Corp signed a contract, regarding merger between Magnolia Acquisition Corp and U.S.-based firm Accelovance,Inc

BRIEF- Linical unit sets up unit LINICAL Czech Republic s.r.o.

* Says its unit LINICAL Europe Holding GmbH set up a wholly owned CRO business unit LINICAL Czech Republic s.r.o., on Sept. 8

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up